Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Beltran Lab
Explore this Website
Home
About Us
Toggle About Us menu options
Contact Us
Job Opportunities
Videos
Affiliations
Research
Lab Team
News
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Affiliations
Research
Lab Team
News
Publications
Home
Publications
Publications
Found 14 results
Author
Title
Type
Year
Filters:
Author
is
Beltran, H
[Clear All Filters]
2016
Beltran H
,
Prandi D
,
Mosquera JM
,
Benelli M
,
Puca L
,
Cyrta J
,
Marotz C
,
Giannopolou E
,
Chakravarthi BV
,
Varambally S
et al.
. 2016.
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
.
Nat Med. 3(22):298-305.
Beltran H
,
Antonarakis ES
,
Morris MJ
,
Attard G
. 2016.
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
.
Am Soc Clin Oncol Educ Book. (35):131-41.
Beltran H
,
Jendrisak A
,
Landers M
,
Mosquera JM
,
Kossai M
,
Louw J
,
Krupa R
,
Graf RP
,
Schreiber NA
,
Nanus DM
et al.
. 2016.
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
.
Clin Cancer Res. 6(22)
Gillessen S
,
Omlin A
,
Attard G
,
de Bono JS
,
Efstathiou E
,
Fizazi K
,
Halabi S
,
Nelson PS
,
Sartor O
,
Smith MR
et al.
. 2016.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
.
Ann Oncol.
Dardenne E
,
Beltran H
,
Benelli M
,
Gayvert K
,
Berger A
,
Puca L
,
Cyrta J
,
Sboner A
,
Noorzad Z
,
MacDonald T
et al.
. 2016.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
.
Cancer Cell. 4(30):563-577.
Choe H
,
Sboner A
,
Beltran H
,
Nanus D
,
Tagawa ST
. 2016.
PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma.
.
Thromb Res. 140 Suppl 1:S192.
2015
Attard G
,
Beltran H
. 2015.
Prioritizing precision medicine for prostate cancer.
.
Ann Oncol. 26(6):1041-2.
2014
Beltran H
,
Tomlins S
,
Aparicio A
,
Arora V
,
Rickman D
,
Ayala G
,
Huang J
,
True L
,
Gleave ME
,
Soule H
et al.
. 2014.
Aggressive variants of castration-resistant prostate cancer.
.
Clin Cancer Res. 20(11):2846-50.
Beltran H
. 2014.
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.
.
Mol Cancer Res. 12(6):815-22.
2013
Mosquera JM
,
Beltran H
,
Park K
,
MacDonald TY
,
Robinson BD
,
Tagawa ST
,
Perner S
,
Bismar TA
,
Erbersdobler A
,
Dhir R
et al.
. 2013.
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
.
Neoplasia . (1):1-10.
Lin PC
,
Giannopoulou EG
,
Park K
,
Mosquera JM
,
Sboner A
,
Tewari AK
,
Garraway LA
,
Beltran H
,
Rubin MA
,
Elemento O
. 2013.
Epigenomic alterations in localized and advanced prostate cancer.
.
Neoplasia. 15(4):373-83.
Beltran H
,
Rubin MA
. 2013.
New strategies in prostate cancer: translating genomics into the clinic.
.
Clin Cancer Res. 19(3):517-23.
Beltran H
,
Yelensky R
,
Frampton GM
,
Park K
,
,
MacDonald TY
,
Jarosz M
,
Lipson D
,
Tagawa ST
,
Nanus DM
et al.
. 2013.
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
.
Eur Urol. 63(5):920-6.
2012
Beltran H
,
Tagawa ST
,
Park K
,
MacDonald T
,
Milowsky MI
,
Mosquera JM
,
Rubin MA
,
Nanus DM
. 2012.
Challenges in recognizing treatment-related neuroendocrine prostate cancer.
.
J Clin Oncol. 30(36):386-9.